Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine Switch for Renal Function in CHB
NCT03778567Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Aug 2013
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by The University of Hong Kong. Primary endpoint: Renal function change at 108 weeks. Started Aug 2013; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03778567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778567.